Meloxicam
ملوکسیکام
🦴 Musculo-Skeletal SystemNSAID
Market / country: 🇺🇸 USA
Mobic (US)
🧮 Dose calculator
Osteoarthritis · Regimen source: FDA Meloxicam · 2.2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity; history of asthma, urticaria or allergic-type reaction after aspirin or other NSAIDs; in the setting of CABG surgery. FDA Meloxicam · 4
- ⚠️ Boxed warning: risk of serious cardiovascular thrombotic events and GI bleeding, ulceration and perforation. FDA Meloxicam · Boxed Warning
Formulations
- 7.5 mg tablet — tablet 🇺🇸 USA FDA Meloxicam · 3
- 15 mg tablet — tablet 🇺🇸 USA FDA Meloxicam · 3
👥 Special populations
- 🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Meloxicam · 8.1
“Clinical Considerations Fetal/Neonatal Adverse Reactions Premature Closure of Fetal Ductus Arteriosus: Avoid use of NSAIDs in women at about 30 weeks gestation and later in pregnancy, because NSAIDs, including meloxicam, can cause premature closure of the fetal ductus arteriosus (see Data).”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Meloxicam · 8.2
“Risk Summary There are no human data available on whether meloxicam is present in human milk, or on the effects on breastfed infants, or on milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Meloxicam · 8.4
“The safety and effectiveness of meloxicam in pediatric JRA patients from 2 years to 17 years of age has been evaluated in three clinical trials [see Dosage and Administration ( 2.3 ), Adverse Reactions ( 6.1 ) and Clinical Studies ( 14.2 )].”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Meloxicam · Boxed Warning
“Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events ( 5.2 ) Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial …”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Meloxicam · 8.3
“Infertility Females Based on the mechanism of action, the use of prostaglandin-mediated NSAIDs, including meloxicam, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women.”
🔗 Reference links
- FDA (approval record)ANDA077921
- DailyMed (FDA label)FDA Meloxicam
- MedlinePlus (NIH)MeloxicamMeloxicam Injection
- WHO ATC/DDDM01AC06
- Darooyab (Iran)Meloxicam
🇮🇷 Registered in Iran Darooyab · G-125/Meloxicam
Dosage forms with Iranian generic codes, per Darooyab.
- 07061 · MELOXICAM 15MG TAB · قرص ملوکسیکام ۱۵ میلیگرم
- 05452 · MELOXICAM 7.5MG TAB · قرص ملوکسیکام ۷٫۵ میلیگرم
- 53101 · MELOXICAM TABLET, ORALLY DISINTEGRATING ORAL 15 mg · قرص بازشونده دهانی ملوکسیکام بازشونده ۱۵ میلیگرم
- 53100 · MELOXICAM TABLET, ORALLY DISINTEGRATING ORAL 7.5 mg · قرص بازشونده دهانی ملوکسیکام بازشونده ۷٫۵ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Meloxicam · 3FDA Meloxicam · 2.2FDA Meloxicam · 2FDA Meloxicam · 2.3FDA Meloxicam · 2.4FDA Meloxicam · 4FDA Meloxicam · Boxed WarningFDA Meloxicam · 8.1FDA Meloxicam · 8.2FDA Meloxicam · 8.4FDA Meloxicam · 8.3FDA Meloxicam · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-125/Meloxicam
- Clinical review⚠ Unverified